Results 161 to 170 of about 485,652 (302)

Population Pharmacokinetic/Toxicodynamic Model for Polymyxin B in Critically Ill Patients to Identify the Risk of Nephrotoxicity

Clinical Pharmacology &Therapeutics, EarlyView.
Polymyxins are used against highly resistant Gram‐negative pathogens, and nephrotoxicity (acute kidney injury, AKI) is the major dose‐limiting adverse effect. We aimed to develop a well‐informed population pharmacokinetic/toxicodynamic (PK/TD) model using the largest polymyxin B‐treated critically ill patient population studied to inform polymyxin B ...
Patrick O. Hanafin, Ramya Mahadevan, Gauri G. Rao, Alexandre P. Zavascki, Ana Maria Sandri, Andrea Kwa, Marc H. Scheetz, Christine J. Kubin, Jayesh Shah, Benjamin P.Z. Cherng, Michael T. Yin, Jiping Wang, Lu Wang, David P. Calfee, Maureen Bolon, Anthony W. Purcell, Roger L. Nation, Jason M. Pogue, Jian Li, Keith S. Kaye   +19 more
wiley   +1 more source

Development of Protected Research Time Guideline for Practitioner Pharmacists: Points to Consider. [PDF]

Hosp Pharm
Balan S, Shirlyn T, Musa N, Jin SL.
europepmc   +1 more source

Optimizing Patient Registries for Regulatory Decision Making ‐ Key Learnings From an HMA/EMA Multistakeholder Workshop

Clinical Pharmacology &Therapeutics, EarlyView.
The Joint Heads of Medicines Agencies and European Medicines Agency's (HMA/EMA) big data initiative paves the way for better integration of real‐world data, including data from patient registries, into regulatory decisions on medicines. This article focuses on the outcome of a two‐day multistakeholder workshop organized by EMA in 2024, which explored ...
Kelly Plueschke, Carla Jonker, Hanna Kankanen, Thorsten Vetter, Bruno Sepodes, Lutz Naehrlich, Jan Hillert, Gracy Crane, Sabine Straus, Paolo Foggi, Simona Martin, Christina Kyriakopoulou, Peter Mol, Francesca Day, Kieran Breen, Neil Bennett, Mencia de Lemus Belmonte, Simon Bennett, Patrice Verpillat, Kit C. B. Roes, Ana Cochino, Franz Schaefer, Jesús María Hernández‐Rivas, Patricia McGettigan, Peter Arlett   +24 more
wiley   +1 more source

Healthcare professionals' perceptions of electronic prescription systems in outpatient services: a qualitative study at UNS hospital. [PDF]

Cost Eff Resour Alloc
Sudarsono J, Satibi S, Lazuardi L, Widayanti AW.   +3 more
europepmc   +1 more source

Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges

Clinical Pharmacology &Therapeutics, EarlyView.
Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing.
D. Max Smith, Michael P. Douglas, Christina L. Aquilante, Patricia A. Deverka, Beth Devine, Henry M. Dunnenberger, Philip E. Empey, Daniel L. Hertz, Andrew A. Monte, Ann M. Moyer, Jai N. Patel, Victoria M. Pratt, Loren Saulsberry, Stuart A. Scott, Deepak Voora, Erica L. Woodahl, Michelle Whirl‐Carrillo, Akinyemi Oni‐Orisan, on behalf of the Pharmacogenomics Global Research Network (PGRN) Publications Committee   +18 more
wiley   +1 more source

A Clinical Pharmacy Service to Prevent Drug-Drug Interactions and Potentially Inappropriate Medication: A Consecutive Intervention Study in Older Intermediate Care Patients of a Regional Hospital. [PDF]

Pharmacy (Basel)
Ullmann AK, Bach O, Mosch K, Bertsche T.
europepmc   +1 more source

CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 loss‐of‐function (LOF) alleles decrease the antiplatelet effect of clopidogrel following percutaneous coronary intervention (PCI) in patients presenting with acute coronary syndrome (ACS). The impact of genotype in patients undergoing PCI for stable ischemic heart disease (SIHD) in real‐world populations is less clear.
Catherine Chanfreau‐Coffinier, Kevin A. Friede, Mary E. Plomondon, Kyung Min Lee, Zhenyu Lu, Tia Dinatale, Scott L. DuVall, Jason L. Vassy, Stephen W. Waldo, John H. Cleator, Thomas M. Maddox, Daniel J. Rader, Themistocles L. Assimes, Scott M. Damrauer, Philip S. Tsao, Kyong‐Mi Chang, Deepak Voora, Julie A. Lynch, Jay Giri, VA Million Veteran Program, Sony Tuteja   +20 more
wiley   +1 more source

Successful management of Candida auris external ventricular shunt infection: a case report. [PDF]

J Med Case Rep
Elhaj A, Jawhar D, Elfaki N.
europepmc   +1 more source

Impact of First‐of‐Its‐Kind Patient‐Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes

Clinical Pharmacology &Therapeutics, EarlyView.
Germline pharmacogenetics (PGx) is increasingly used to tailor medication selection/dosing. However, existing systems primarily communicate PGx results to providers, limiting direct patient engagement. To address this, we developed YourPGx Oncology, an innovative patient‐facing portal that delivers multi‐gene PGx results (CYP2D6, UGT1A1, DPYD) through ...
Youngwoo Cho, Sami Elahi, Matthew M. Jack, John Campbell, Emily Smith, Randall W. Knoebel, David George, Larry House, Kiang‐Teck J. Yeo, Theodore Karrison, Samuel L. Volchenboum, David O. Meltzer, Russell Z. Szmulewitz, Everett E. Vokes, Mark J. Ratain, Peter H. O'Donnell   +15 more
wiley   +1 more source

Evaluation of Patient-Driven Constipation Action Plans for Patients Discharged From a Pediatric Hospitalist Service. [PDF]

J Pediatr Pharmacol Ther
Kiss Z, Allison A, Knopp M.
europepmc   +1 more source